^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
11/20/2015
Excerpt:
NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Evidence Level:
Sensitive: A2 - Guideline
Title:

NICE approves ixazomib in combination with lenalidomide–dexamethasone to treat relapsed or refractory multiple myeloma

Published date:
01/23/2023
Excerpt:
The National Institute for Health and Care Excellence (NICE) published a guidance document recommending the use of ixazomib (brand name Ninlaro) in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Multiple Myeloma:…the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as an option (category 2B) for treatment of patients with newly diagnosed MM....the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as a category 1, preferred regimen option for previously treated MM.